iBio, Inc. (IBIO)

Last Closing Price: 1.89 (2026-05-21)

Company Description

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.40M
Net Income (Most Recent Fiscal Year) $-18.38M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.88
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -9202.00%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -53.86%
Return on Assets (Trailing 12 Months) -46.48%
Current Ratio (Most Recent Fiscal Quarter) 11.88
Quick Ratio (Most Recent Fiscal Quarter) 11.88
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $1.56
Earnings per Share (Most Recent Fiscal Quarter) $-0.07
Earnings per Share (Most Recent Fiscal Year) $-1.75
Diluted Earnings per Share (Trailing 12 Months) $-0.58
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 49.68M
Free Float 35.15M
Market Capitalization $93.89M
Average Volume (Last 20 Days) 1.05M
Beta (Past 60 Months) 1.23
Percentage Held By Insiders (Latest Annual Proxy Report) 2.75%
Percentage Held By Institutions (Latest 13F Reports) 7.90%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%